Chonnam Med J.  2010 Apr;46(1):38-43. 10.4068/cmj.2010.46.1.38.

The Relationship between the Levels of Lipoprotein (a) and Fibrinogen and Clinical Outcome in Patients with Acute Myocardial Infarction

• Kim SH
• Jeong MH
• Lee MG
• Ko JS
• Park KH
• Sim DS
• Hong YJ
• Kim JH
• Ahn Y
• Kang JC

• KMID: 2172255
• DOI: http://doi.org/10.4068/cmj.2010.46.1.38

Abstract

The aim of this study was to evaluate clinical outcomes in patients with acute myocardial infarction (AMI) on the basis of serum levels of lipoprotein (a) [Lp(a)] and fibrinogen. A total of 537 consecutive patients (62.4+/-12.3 years) diagnosed with AMI between January 2006 and December 2007 were divided into four groups according to serum levels of Lp(a) and fibrinogen on admission [group I: normal Lp(a) and normal fibrinogen levels (n=235); group II: elevated Lp(a) and normal fibrinogen levels (n=100); group III: normal Lp(a) and elevated fibrinogen levels (n=105); group IV: elevated Lp(a) and elevated fibrinogen levels (n=95)]. The baseline clinical characteristics showed significant differences between the four groups in age (p<0.001), body mass index (p=0.025), N-terminal pro-brain natriuretic peptide levels (p<0.001), left ventricular ejection fraction (p<0.001), and echocardiographic wall motion scores (p<0.001). In the coronary angiographic findings, the number of diseased vessels was higher?and involvement of the left anterior descending artery was more common in group IV than in group I (1.8+/-0.9 vs. 1.5+/-0.8, p=0.001, and 65% vs. 51%, p=0.042, respectively). Likewise, in-hospital and 1-month major adverse cardiac events were more frequent in group IV than in group I (4.2% vs. 1.3%, p=0.037, and 14.1% vs. 3.1%, p<0.001, respectively). In conclusion, AMI patients with high Lp(a) or fibrinogen levels had worse clinical outcomes than did patients with normal levels of Lp(a) and fibrinogen.

Keyword

Lipoproteins; Fibrinogen; Prognosis

MeSH Terms

Arteries
Body Mass Index
Fibrinogen
Humans
Lipoprotein(a)
Lipoproteins
Myocardial Infarction
Prognosis
Stroke Volume
Fibrinogen
Lipoprotein(a)
Lipoproteins

Reference

1. Suh I. Cardiovascular mortality in Korea: a country experiencing epidemiologic transition. Acta Cardiol. 2001. 56:75–81.

2. Berg K. A new serum type system in man--the Lp system. Acta pathol Microbiol Scand. 1963. 59:369–382.

3. Lee HB. Non-insulin-dependent diabetes mellitus, proteinuria, and Lipoprotein (a). Korean J Med. 1999. 57:136–138.

4. Marcovina SM, Albers JJ, Scanu AM, Kennedy H, Giaculli F, Berg K, et al. Use of reference material proposed by the international federation of clinical chemistry and laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein (a). Clin Chem. 2000. 46:1956–1967.

5. Tan V, Doyle CJ, Budzynski AZ. Comparison of the kinetic fibrinogen assay with the von Clauss method and the clot recovery method in plasma of patients with conditions affecting fibrinogen coagulability. Am J Clin Pathol. 1995. 104:455–462.

6. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the let ventricle by two-dimensional echocardiography. American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr. 1989. 2:358–367.

7. Gambhir JK, Kaur H, Prabhu KM, Morrisett JD, Gambhir DS. Association between lipoprotein (a) levels, apo (a) isoforms and family history of premature CAD in young Asian Indians. Clin Biochem. 2008. 41:453–458.

8. Ebesunun MO, Agbedana EO, Taylor GO, Oladapo OO. Plasma lipoprotein (a), homocysteine, and other cardiovascular disease (CVD) risk factors in Nigerians with CVD. Appl Physiol Nutr Metab. 2008. 33:282–289.

9. Hartmann M, von Birgelen C, Mintz GS, Stoel MG, Eggebrecht H, Wieneke H, et al. Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasoundplaque progression in left main coronary arteries. J Am Coll Cardiol. 2006. 48:446–452.

10. Kamstrup PR, Benn M, Tybaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008. 117:176–184.

11. Barre DE. The molecular nature and consequences of lipoprotein (a)'s association with platelets. Protein Pept Lett. 2007. 14:839–842.

12. Fujii C, Sakakibara H, Kondo T, Yatsuya H, Tamakoshi K, Toyoshima H. Plasma fibrinogen levels and cardiovascular risk factors in Japanese school children. J Epidemiol. 2006. 16:64–70.

13. Mannila MN, Lovely RS, Kazmierczak SC, Eriksson P, Samnegård A, Farrell DH, et al. Elevated plasma fibrinogen gamma' concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemos. 2007. 5:766–773.

14. Green D, Foiles N, Chan C, Schreiner PJ, Liu K. Elevated fibrinogen levels and subsequent subclinical atherosclerosis: the CARDIA Study. Atherosclerosis. 2009. 202:623–631.

15. Ganotakis ES, Gazi IF, Papadakis JA, Jagroop IA, Nair DR, Mikhailidis DP. The relationship between circulating fibrinogen and lipoprotein (a) levels in patients with primary dyslipidemia. Clin Appl Thromb Hemost. 2007. 13:35–42.

16. Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke. 2007. 38:1959–1966.

17. Shah HD, Parikh KH, Chag MC, Shah UG, Baxi HA, Chandarana AH, et al. Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. Exp Clin Cardiol. 2007. 12:91–96.

18. Shin MJ, Blanche PJ, Rawlings RS, Fernstrom HS, Krauss RM. Increased plasma concentrations of lipoprotein(a) during a low-fat, high-carbohydrate diet are associated with increased plasma concentrations of apolipoprotein C-III bound to apolipoprotein B-containing lipoproteins. Am J Clin Nutr. 2007. 85:1527–1532.

19. Albahrani AI, Usher JJ, Alkindi M, Marks E, Ranganath L, Al-yahyaee S. Apolipoprotein A1-75 G/A (M1-) polymorphism and lipoprotein (a); anti- vs. pro-atherogenic properties. Lipids Health Dis. 2007. 6:19.

20. Mannila MN, Lovely RS, Kazmierczak SC, Eriksson P, Samnegård A, Farrell DH, et al. Elevated plasma fibrinogen gamma' concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemost. 2007. 5:766–773.

21. Joy MS, Dornbrook-Lavender KA, Chin H, Hogan SL, Denu-Ciocca C. Effects of atorvastatin on lipoprotein (a) and lipoprotein profiles in hemodialysis patients. Ann Pharmacother. 2008. 42:9–15.

22. Murabito JM, Keyes MJ, Guo CY, Keaney JF Jr, Vasan RS, D'Agostino RB Sr, et al. Cross-sectional relations of multiple inflammatory biomarkers to peripheral arterial disease: the framingham offspring study. Atherosclerosis. 2009. 203:509–514.

23. Zakai NA, Katz R, Jenny NS, Psaty BM, Reiner AP, Schwartz SM, et al. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. J Thromb Haemost. 2007. 5:1128–1135.

24. Sattar N, Williams K, Sniderman AD, D'Agostino R Jr, Haffner SM. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation. 2004. 110:2687–2693.

25. Murase T, Okubo M, Amemiya-Kudo M, Hiraga T, Oka J, Shimada M, et al. Impact of markedly elevated serum lipoprotein(a) levels (>or = 100 mg/dL) on the risk of coronary heart disease. Metabolism. 2007. 56:1187–1191.

26. Páramo JA, Beloqui O, Roncal C, Benito A, Orbe J. Validation of plasma fibrinogen as a marker of carotid atherosclerosis in subjects free of clinical cardiovascular disease. Haematologica. 2004. 89:1226–1231.

27. Park OY, Kim SH, Ahn YK, Yun NS, Kim JH, Sim DS, et al. Statin reduces C-reactive protein and interleukin-6 in normocholesterolemic patients with acute coronary syndrome. Chonnam Med J. 2008. 44:13–16.